Agravamento do sintoma depressão em pacientes com Doença de Parkinson na pandemia da COVID-19: uma revisão sistemática
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Dec 28, 2022
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Investigar na literatura se houve aumento dos sintomas depressivos em pacientes com Doença de Parkinson, na pandemia da COVID-19. Métodos: A revisão sistemática foi executada de acordo com o protocolo de Revisões Sistemáticas e Meta-Análises (PRISMA), registrada no PROSPERO sob o número CRD 42021289109. A busca dos artigos foi realizada em agosto de 2021, utilizando os descritores "Parkinson’s Disease", "COVID-19" e "Depression", combinados com o operador AND, nas bases de dados: PubMed, PsycInfo e Biblioteca Virtual em Saúde (BVS). Foram identificados 67 registros e avaliados 29 artigos, dos quais 10 foram incluídos nesta revisão. Resultados: A maioria dos estudos reportaram diferença significativa nos escores de depressão, sugerindo que no período pandêmico os pacientes sofreram agravamento deste sintoma não motor. Os achados reportam que a escassez de apoio familiar, redução de atividade física e estresse relacionado a COVID-19, são alguns dos principais fatores que influenciaram o agravamento da depressão. Considerações Finais: Os limites estabelecidos pelo momento da pandemia e o isolamento social, ocasionaram, mesmo que de maneira reduzida, o agravamento da depressão na população estudada.
##plugins.themes.bootstrap3.article.details##
Como Citar
VenturaS. de A., MirandaI. P., & SantosR. M. S. (2022). Agravamento do sintoma depressão em pacientes com Doença de Parkinson na pandemia da COVID-19: uma revisão sistemática. Revista Eletrônica Acervo Saúde, 15(12), e11340. https://doi.org/10.25248/reas.e11340.2022
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ASSOGNA F, et al. Drug Choices and Advancements for Managing Depression in Parkinson’s Disease. Current Neuropharmacology, 2020; 18(4): 277–287.
2. BALCI B, et al. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson’s disease. International Journal of Rehabilitation Research, 2021; 44(0342): 173–176.
3. BEZERRA KP, et al. Ensino remoto em universidades públicas estaduais: O futuro que se faz presente. Research, Society and Development, 2020; 9(9): 1–17.
4. CABREIRA V e MASSANO J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Médica Portuguesa, 2019; 32(10): 661–670.
5. CHAKRABORTY I e MAITY P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of the Total Environment, 2020; 728: 1–7.
6. DE RUS JACQUET A, et al. Clinical perception and management of Parkinson’s disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism and Related Disorders, 2021;91: 66–76.
7. DITZEN B e HEINRICHS M. Psychobiology of social support: The social dimension of stress buffering. Restorative Neurology and Neuroscience, 2014; 32: 149–162.
8. DOMINGOS J, et al. Is Being Physically Active Enough or Do People with Parkinson’s Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19. International Journal of Environmental Research and Public Health, 2022; 19(4): 1–12.
9. DOMMERSHUIJSEN LJ, et al. Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions? NPJ Parkinson's disease, 2021; 7(1): 1-9.
10. DORSEY ER e BLOEM BR. The Parkinson pandemic - A call to action. JAMA Neurology, 2018; 75(1): 9–10.
11. DRAGAŠEVIĆ-MIŠKOVIĆ NT, et al. Impact of depression on gait variability in Parkinson's disease. Clin Neurol Neurosurg, 2021; 200(106324).
12. EL OTMANI H, et al. No impact of confinement during COVID-19 pandemic on anxiety and depression in Parkinsonian patients. Revue Neurologique, 2021; 177(3): 272–274.
13. FALLA M, et al. Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study. Acta neurologica Belgica, 2021; 121(5): 1191–1198.
14. GAZEWOODJD, et al. Parkinson disease: An update. American Family Physician, 2013;87(4): 267–273.
15. HAAS AN, et al. Association between mental health and physical activity levels in people with Parkinson’s disease during the COVID-19 pandemic: an observational cross-sectional survey in Brazil. Sport Sciences for Health, 2022; 1–7.
16. HELMY A, et al. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022; 58(9): 1–10.
17. HIGGINS JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online), 2011; 343(7829): 1–9.
18. HUANG T-T, et al. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-dwelling elderly adults: A randomized controlled trial. International journal of nursing studies. Int J Nurs Stud, 2015; (52): 1542–52.
19. JANIRI D, et al. COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson’s Disease in the Elderly. Frontiers in Psychiatry, 2020; 11: 1–8.
20. KETIGIAN L, et al. Transition and Sustainability of an Online Care Model for People with Parkinson's Disease in Response to the COVID-19 Pandemic. Frontiers in public health, 2022; 9(772805): 1-10.
21. KITANI-MORII F, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS ONE, 2021; 16(1): 1–13.
22. KNAPIK A, et al. Isolation Related to the COVID-19 Pandemic in People Suffering from Parkinson’s Disease and Activity, Self-Assessment of Physical Fitness and the Level of Affective Disorders. Healthcare, 2021; 9(11): 1-8.
23. KWOK JYY, et al. Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson’s disease. BMC Complementary Medicine and Therapies, 2022; 22(37): 1–12.
24. MONTANARO E, et al. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurological Sciences, 2021; 43(1): 341–348.
25. PFEIFFER RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism and Related Disorders, 2015; 22: 1–4.
26. PONTONE GM, MILLS KA. Optimal Treatment of Depression and Anxiety in Parkinson's Disease. The American journal of geriatric psychiatry, 2021; 29(6): 530–540.
27. RASS V, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2021; 31: 1401–1414.
28. RIZEK P, et al. An update on the diagnosis and treatment of Parkinson disease. CMAJ, 2016; 188(16): 1157–1165.
29. SAVICA R, et al. When do a-Synucleinopathies start? An epidemiological timeline a review. JAMA Neurology, 2018; 75(4): 503–509.
30. SHALASH A, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID-19 Pandemic. Movement Disorders, 2020; 35(7): 1097–1099.
31. SHAMSEER L, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ (Online), 2015; 349: 1–25.
32. SUBRAMANIAN I, et al. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. npj Parkinson’s Disease, 2020; 6(28): 1–8.
33. SUZUKI K, et al. Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture. Journal of Parkinson’s Disease, 2021; 11(3): 1047–1056.
34. VAN DER HEIDE A, et al. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease, 2020; 10(4): 1355–1364.
35. VENKATESH AES e EDIRAPPULI S. Social distancing in covid-19: what are the mental health implications? BMJ (Clinical research ed.), 2020; 368(1089): 1.
36. VOON V, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology, 2017; 16(3): 238–250.
37. WALTON L, et al. Digital Dance for People with Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study. Frontiers in neurology, 2022; 12(743432).
38. WANG Z, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA neurology, 2020; 78(1): 1–11.
39. WORLD HEALTH ORGANIZATION. Depression and Other Common Mental Disorders: Global Health Estimates. 2017. Disponível em: https://apps.who.int/iris/handle/10665/254610. Acessado em: 12 de fevereiro de 2021.
40. WU PL, et al. Effectiveness of physical activity on patients with depression and Parkinson’s disease: A systematic review. PLoS ONE, 2017; 12(7): 1–14.
41. XIA Y, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 2020; 75: 428–433.
42. XU Y, et al. COVID-19 manifestations in people with Parkinson’s disease: a USA cohort. Journal of Neurology, 2022; 269(3): 1107–1113.
2. BALCI B, et al. Impact of the COVID-19 pandemic on physical activity, anxiety, and depression in patients with Parkinson’s disease. International Journal of Rehabilitation Research, 2021; 44(0342): 173–176.
3. BEZERRA KP, et al. Ensino remoto em universidades públicas estaduais: O futuro que se faz presente. Research, Society and Development, 2020; 9(9): 1–17.
4. CABREIRA V e MASSANO J. Doença de Parkinson: Revisão Clínica e Atualização. Acta Médica Portuguesa, 2019; 32(10): 661–670.
5. CHAKRABORTY I e MAITY P. COVID-19 outbreak: Migration, effects on society, global environment and prevention. Science of the Total Environment, 2020; 728: 1–7.
6. DE RUS JACQUET A, et al. Clinical perception and management of Parkinson’s disease during the COVID-19 pandemic: A Canadian experience. Parkinsonism and Related Disorders, 2021;91: 66–76.
7. DITZEN B e HEINRICHS M. Psychobiology of social support: The social dimension of stress buffering. Restorative Neurology and Neuroscience, 2014; 32: 149–162.
8. DOMINGOS J, et al. Is Being Physically Active Enough or Do People with Parkinson’s Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19. International Journal of Environmental Research and Public Health, 2022; 19(4): 1–12.
9. DOMMERSHUIJSEN LJ, et al. Mental health in people with Parkinson’s disease during the COVID-19 pandemic: potential for targeted interventions? NPJ Parkinson's disease, 2021; 7(1): 1-9.
10. DORSEY ER e BLOEM BR. The Parkinson pandemic - A call to action. JAMA Neurology, 2018; 75(1): 9–10.
11. DRAGAŠEVIĆ-MIŠKOVIĆ NT, et al. Impact of depression on gait variability in Parkinson's disease. Clin Neurol Neurosurg, 2021; 200(106324).
12. EL OTMANI H, et al. No impact of confinement during COVID-19 pandemic on anxiety and depression in Parkinsonian patients. Revue Neurologique, 2021; 177(3): 272–274.
13. FALLA M, et al. Lockdown effects on Parkinson’s disease during COVID-19 pandemic: a pilot study. Acta neurologica Belgica, 2021; 121(5): 1191–1198.
14. GAZEWOODJD, et al. Parkinson disease: An update. American Family Physician, 2013;87(4): 267–273.
15. HAAS AN, et al. Association between mental health and physical activity levels in people with Parkinson’s disease during the COVID-19 pandemic: an observational cross-sectional survey in Brazil. Sport Sciences for Health, 2022; 1–7.
16. HELMY A, et al. Baseline predictors of progression of Parkinson’s disease in a sample of Egyptian patients: clinical and biochemical. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2022; 58(9): 1–10.
17. HIGGINS JPT, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Online), 2011; 343(7829): 1–9.
18. HUANG T-T, et al. Physical fitness exercise versus cognitive behavior therapy on reducing the depressive symptoms among community-dwelling elderly adults: A randomized controlled trial. International journal of nursing studies. Int J Nurs Stud, 2015; (52): 1542–52.
19. JANIRI D, et al. COVID-19 Pandemic and Psychiatric Symptoms: The Impact on Parkinson’s Disease in the Elderly. Frontiers in Psychiatry, 2020; 11: 1–8.
20. KETIGIAN L, et al. Transition and Sustainability of an Online Care Model for People with Parkinson's Disease in Response to the COVID-19 Pandemic. Frontiers in public health, 2022; 9(772805): 1-10.
21. KITANI-MORII F, et al. Risk factors for neuropsychiatric symptoms in patients with Parkinson’s disease during COVID-19 pandemic in Japan. PLoS ONE, 2021; 16(1): 1–13.
22. KNAPIK A, et al. Isolation Related to the COVID-19 Pandemic in People Suffering from Parkinson’s Disease and Activity, Self-Assessment of Physical Fitness and the Level of Affective Disorders. Healthcare, 2021; 9(11): 1-8.
23. KWOK JYY, et al. Stay mindfully active during the coronavirus pandemic: a feasibility study of mHealth-delivered mindfulness yoga program for people with Parkinson’s disease. BMC Complementary Medicine and Therapies, 2022; 22(37): 1–12.
24. MONTANARO E, et al. Anxiety, depression, and worries in advanced Parkinson disease during COVID-19 pandemic. Neurological Sciences, 2021; 43(1): 341–348.
25. PFEIFFER RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism and Related Disorders, 2015; 22: 1–4.
26. PONTONE GM, MILLS KA. Optimal Treatment of Depression and Anxiety in Parkinson's Disease. The American journal of geriatric psychiatry, 2021; 29(6): 530–540.
27. RASS V, et al. Factors associated with impaired quality of life three months after being diagnosed with COVID-19. Quality of Life Research, 2021; 31: 1401–1414.
28. RIZEK P, et al. An update on the diagnosis and treatment of Parkinson disease. CMAJ, 2016; 188(16): 1157–1165.
29. SAVICA R, et al. When do a-Synucleinopathies start? An epidemiological timeline a review. JAMA Neurology, 2018; 75(4): 503–509.
30. SHALASH A, et al. Mental Health, Physical Activity, and Quality of Life in Parkinson’s Disease During COVID-19 Pandemic. Movement Disorders, 2020; 35(7): 1097–1099.
31. SHAMSEER L, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ (Online), 2015; 349: 1–25.
32. SUBRAMANIAN I, et al. Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life. npj Parkinson’s Disease, 2020; 6(28): 1–8.
33. SUZUKI K, et al. Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Parkinson’s Disease and Their Caregivers: A Single-Center Survey in Tochigi Prefecture. Journal of Parkinson’s Disease, 2021; 11(3): 1047–1056.
34. VAN DER HEIDE A, et al. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. Journal of Parkinson’s Disease, 2020; 10(4): 1355–1364.
35. VENKATESH AES e EDIRAPPULI S. Social distancing in covid-19: what are the mental health implications? BMJ (Clinical research ed.), 2020; 368(1089): 1.
36. VOON V, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. The Lancet. Neurology, 2017; 16(3): 238–250.
37. WALTON L, et al. Digital Dance for People with Parkinson's Disease During the COVID-19 Pandemic: A Feasibility Study. Frontiers in neurology, 2022; 12(743432).
38. WANG Z, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA neurology, 2020; 78(1): 1–11.
39. WORLD HEALTH ORGANIZATION. Depression and Other Common Mental Disorders: Global Health Estimates. 2017. Disponível em: https://apps.who.int/iris/handle/10665/254610. Acessado em: 12 de fevereiro de 2021.
40. WU PL, et al. Effectiveness of physical activity on patients with depression and Parkinson’s disease: A systematic review. PLoS ONE, 2017; 12(7): 1–14.
41. XIA Y, et al. Investigation on sleep and mental health of patients with Parkinson’s disease during the Coronavirus disease 2019 pandemic. Sleep Medicine, 2020; 75: 428–433.
42. XU Y, et al. COVID-19 manifestations in people with Parkinson’s disease: a USA cohort. Journal of Neurology, 2022; 269(3): 1107–1113.